Regulation and Function of ILC3s in Pulmonary Infections

Joseph P. Hoffmann, Jay K. Kolls and Janet E. McCombs*

Center for Translational Research in Infection & Inflammation, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, United States

Lower respiratory infections are among the leading causes of morbidity and mortality worldwide. These potentially deadly infections are further exacerbated due to the growing incidence of antimicrobial resistance. To combat these infections there is a need to better understand immune mechanisms that promote microbial clearance. This need in the context of lung infections has been further heightened with the emergence of SARS-CoV-2. Group 3 innate lymphoid cells (ILC3s) are a recently discovered tissue resident innate immune cell found at mucosal sites that respond rapidly in the event of an infection. ILC3s have clear roles in regulating mucosal immunity and tissue homeostasis in the intestine, though the immunological functions in lungs remain unclear. It has been demonstrated in both viral and bacterial pneumonia that stimulated ILC3s secrete the cytokines IL-17 and IL-22 to promote both microbial clearance as well as tissue repair. In this review, we will evaluate regulation of ILC3s during inflammation and discuss recent studies that examine ILC3 function in the context of both bacterial and viral pulmonary infections.

Keywords: ILC3, innate lymphoid cell (ILC), pneumonia, SARS-CoV-2, COVID-19, Klebsiella pneumoniae, Streptococcus pneumoniae, Pseudomonas aeruginosa

INTRODUCTION

Th1 and Th2 helper cell subsets were initially defined by cytokine secretion (1, 2) and this was expanded to other T cell subsets including Th17 cells in the early 2000s, which demonstrated that IL-17 secreting CD4+ T cells arise independent of transcription factors of Th1 (STAT4) and Th2 (STAT6) cells (3–5). However, shortly after the expansion of these Th subsets, it was recognized that many of these cytokines could also be produced by non-T-cell receptor bearing innate cells such as IFNγ-producing NK cells. Th2 cytokines, such as IL-5 and IL-13, were found to be expressed in innate lymphoid cells (ILCs) by several groups (6, 7) and these cells have been subsequently termed group 2 or ILC2 cells. Similarly, cytokines associated with Th17 lineage, IL-17 and IL-22, were originally found in ILCs within tonsils and the gastrointestinal tract (8, 9) and termed group 3 or ILC3 cells. A key early finding showing the functionality of ILC3 cells was demonstrating that they could mediate colitis in mice lacking T cells (9). As opposed to the gastrointestinal tract, where ILC3 cells are abundant, ILC2 cells predominate in the lung, seeding tissues during fetal development (10, 11). However, it has been increasingly recognized that ILC3s play a role in lung immunity. Like other ILC populations, ILC3s require IL-7R signaling and derive from Id2 expressing progenitor cells (12). ILC3s also express the transcription factor RORγt, which differentiates them from ILC1 or ILC2 cells. This review will highlight recent advances in ILC3 biology in the lung.
REGULATION OF ILC3 IN THE LUNG

ILC3s localized to the lung are ideally positioned to regulate mucosal immunity within the context of constant exposure to environmental insults. Indeed, in newborn mice, insulin-like growth factor 1 (IGF1)-dependent maturation and expansion of ILC3 precursors in lungs was essential for protection against respiratory pathogens (13). Importantly, disruption of ILC3 development in neonates resulted in increased susceptibility to infection into adulthood, emphasizing the importance of early establishment of these surveymen of lung health. Several chemokines may facilitate ILC3 positioning in the lung. The CXCL13-CXCR5 axis has been implicated in localization of ILC3 to inducible bronchial associated lymphoid tissue (iBALT) structures that develop in the lungs in Mycobacterium tuberculosis infection in mice (14), while both CCR6 and CXCR5 were expressed by ILC3s recruited to sites of lung tumors in patients (15). Trafficking of ILC3s to the lung during pneumonia was attributed to CCR4 expression, as deficiency of CCR4 in adoptively transferred ILC3s abrogated homing to the lungs in newborn mice (16). This study also demonstrated the possibility that some lung ILC3 populations may derive from circulating ILC3s. Finally, the CXCR6-CXCL16 axis, which is critical for ILC3 precursor localization to the mouse lamina propria (17), enabled homing of ILC1 and ILC2 cells to the lung under inflammatory conditions (18).

Further studies that define mechanisms for how ILC3s or their progenitors traffic to and function in the lung are much-needed, as research on ILC3s largely centers on the gastrointestinal tract where large populations of these cells reside. This gap in knowledge likely stems from the difficulty of studying these cells, as ILC3s comprise < 5% of total ILCs in the mouse lung (19). Similarly, in human lungs, frequencies of IFNγ+ ILCs were higher than IL-17+ or IL-22+ ILCs, though ILC3 and ILC3-like cells encompassed the highest percentage of total ILCs. However, in chronic obstructive pulmonary disease that is associated with iBALT and chronic infection, the percentage of ILC3 cells were increased compared to healthy lung tissue (20), suggesting that environmental exposures may be key drivers of ILC3 accumulation and that studies in mice will need to include modeling such exposures to study ILC3 biology.

Once in the lung, ILC3s are believed to primarily reside in their resident tissue. Parabiosis studies in uninfected mice revealed that > 95% of all ILCs from various tissues were of host origin (21), though ILC3s were not analyzed in the lungs, perhaps due to the low numbers of these cells at rest (19). However, evidence also supports an increase in circulating ILCs can occur during inflammation. Indeed, helminth infection of mice induced an increase in circulating ILC3s derived from the small intestine and lung (22, 23), though only lung-derived ILC2 were able to migrate back into the lung (23). Commensal bacteria in the intestines of newborn mice were also found to induce expression of CCR4 on ILC3s, enabling subsequent migration to the lungs during pneumonia (16). Nevertheless, analysis of human blood found low numbers of ILC3s in circulation at rest (24), suggesting that while mature ILC3s may migrate during inflammation, the majority of ILC3s may reside and proliferate within their resident tissue.

As ILC3s do not bear T-cell receptors, other factors including cytokines, alarmins, and co-stimulatory molecules can mediate ILC3 stimulation to induce effector function. ILC3s provide immune surveillance of the lung at the steady state, delivering immediate innate protection after host exposure to pathogens. During inflammation, IL-1β and IL-23 stimulate ILC3s to produce IL-17 and IL-22 (8, 25), which in turn regulate epithelial barrier function and mediate host response to infections (8, 26, 27). In the lungs, these cytokines function to enhance production of antimicrobial proteins, facilitate barrier repair through promotion of epithelial cell proliferation, and augment neutrophil recruitment, resulting in increased clearance of pulmonary pathogens (28-30). Thus, activated ILC3s are well-poised to provide immediate and direct action toward foreign antigens. Importantly, ILC2s may also provide IL-17-mediated benefits upon infection. Indeed, ILC2s from nasal polyps of cystic fibrosis patients or skin lesions of psoriasis patients transdifferentiated to an ILC3-like cell—expressing RORγt and producing IL-17—upon ex vivo stimulation with IL-1β, IL-23, and TGFβ (31, 32). Therefore, given the abundance of ILC2 in the lung, their potential for plasticity could contribute to ILC3-attributed functions during inflammation.

The inducible T cell costimulatory molecule (ICOS) may also stimulate ILC3s in the lung. Differential expression of ICOS, which is also expressed on T cells, has been observed in both mouse and human ILC3s (33, 34). However, the role of this molecule in regulating ILC3 function remains to be fully determined. Mice deficient in ICOS had no change in the total amount of ILC3 in the lung at rest compared to their wild-type counterparts (19), though < 2% of ILCs studied were ILC3s. As not all ILC3s express ICOS, it is possible in the deficient background the balance between ICOS+ and ICOS- ILC3s is shifted, especially since the total population of ILC3s in the lung at rest is very low (19, 20). Indeed, we have shown administration of a neutralizing anti-ICOS antibody to mice prior to bacterial infection resulted in a decrease in Icos expression as well as expression of Il17 and Il22 after infection with Klebsiella pneumoniae (33). In addition, ex vivo stimulation of ILC3s isolated from K. pneumoniae infected mice with ICOS ligand (ICOSL) resulted in proliferation of cells (33), indicating the ICOS : ICOSL pathway may be important in mediating ILC3 function and proliferation (Figure 1). Interestingly, mouse and human ILC2s express both ICOS and functional ICOSL (35) which can stimulate ICOS+ Treg cells (36), raising the possibility that a coordinated interplay could also exist between ILC3 and ICOSL-expressing ILC2. Such interactions could play a key role in regulating ILC3 activation and providing a swift response upon pathogen presentation in the lungs.

Recent data also suggests a role for the aryl hydrocarbon receptor (AhR) in mediating ILC3 function in the lungs. AhR is an environmental sensor expressed in barrier tissue cells that is critical for ILC3 maintenance and function in the gut (37). Within the environment of the lungs, AhR tunes immune responses to a variety of insults through regulation of ILC3s.
Indeed, Ahr\textsuperscript{−/−} mice displayed a decrease in ILC3s during pulmonary paracoccidioidomycosis (38), indicating this receptor could be critical for expansion or recruitment of ILC3 to sites of infection within the lung. In support of this, activation of AhR resulted in recruitment of ILC3 during chronic exposure of mice to ozone (39).

**ILC3s IN BACTERIAL PNEUMONIA**

Even in an era of antimicrobial treatments, pneumonia remains the leading cause of morbidity and mortality in children aged 28 days to 5 years (40, 41). Among the most common etiological bacterial agents in these cases of pneumonia are pathogens such as *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae* (41–43). Since the discovery of the cytokine IL-17 in 1993 and its receptor in 1995, IL-17 has been demonstrated to be critical in protection against extracellular bacteria and fungi. Further, the coregulated cytokine IL-22 has been shown to promote epithelial integrity and tissue repair at barrier surfaces such as in the gut and lung following inflammation (44). As ILC3s are maintained in lung tissue and can rapidly produce IL-17 and IL-22 upon stimulation, it is clear that they play an important role in the innate immune response against bacterial pneumonia (45).

Though the discovery of ILC3s is recent, there have been numerous studies that have linked ILC3s to bacterial clearance in lung infections. A recent study illustrated that antibody depletion of IL-17 decreases mouse survival against *K. pneumoniae* by 50%. Further, IL-17 induction occurs within the first 3 hours of infection...
suggesting it is mediated by innate cells such as ILC3s or γδ T cell rather than Th17 cells. In T- and B-cell-deficient Rag2−/− mice, the dominant source of IL-17 is ILC3 cells. Depletion of these cells using anti-CD90 or Rag2−/− mice that also are deficient in Il2rg (a common cytokine receptor for IL-7, among other cytokines) ablated IL-17 expression and exacerbated pulmonary infection with K. pneumoniae (46). It is important to recognize that due to limited ILC3 depletion models, these studies only illustrate that ILC3s are sufficient to clear infection in 1-cell-deficient mice. Further studies are required to determine whether ILC3s are required for clearance. Using single cell RNA sequencing, we determined IL-17+, IL-22+, and ICOS+ ILC3s are imperative to protection against carbapenem resistant ILC3s are sufficient to clear infection in 1-cell-deficient mice. Further studies are required to determine whether ILC3s are required for clearance. Using single cell RNA sequencing, we determined IL-17+, IL-22+, and ICOS+ ILC3s are imperative to protection against carbapenem resistant K. pneumoniae in a murine challenge model (33). This study also demonstrated that lung burdens in Rag2−/Il2rg−/− mice can be significantly reduced through the addition of exogenous IL-22.

ILC3s also play a role in the clearance of S. pneumoniae in murine models of lung infection. One group found that lethal challenge with intranasal S. pneumoniae resulted in increased IL-22, IL-17A, and IL-17F expression in lung tissue within 24 hours suggesting a rapid innate response (45). ILC3s appeared to be sufficient for this response as infected Rag2−/− mice had no change in IL-22 levels compared to wild-type controls, while Rag2−/− mice were unable to produce IL-22 upon S. pneumoniae infection. While these models demonstrate the utility of ILC3s in response to S. pneumoniae, future studies are required to demonstrate their necessity. Boosting of ILC3 function could prove therapeutic, as treatment with flagellin at the time of S. pneumoniae infection enhanced IL-22 expression in ILC3s and decreased bacterial burdens in mice (45). This was supported by previous findings that treatment with flagellin enhanced ILC3 production of IL-17 and IL-22 in the intestinal lamina propria and spleen (47, 48). The importance of ILC3s in S. pneumoniae infections in the neonatal period was demonstrated by Gray et al. This group found that in newborn mouse lungs, 90% of the cells producing IL-22 carried the phenotypic markers of ILC3. Depleting ILC3s by administering diphtheria toxin to RORγt−/−/DTR mice dramatically increased their susceptibility to S. pneumoniae and all mice succumbed to infection within 20 hours. Adoptive transfer of ILC3s into the ILC3-depleted mice restored their resistance to S. pneumoniae (16). More recently, it was found that intranasal administration of interleukin 7, an important factor for RORγt+ cell survival and homeostasis, increased the number of RORγt+ innate T cells in the lung, enhanced expression of IL-17A, and reduced bacterial burdens upon S. pneumoniae challenge (49).

Many additional studies since the early 2000s characterize the importance of early IL-17 and IL-22 expression in the clearance of bacterial lung infections. Though these studies do not specifically investigate ILC3s, the ability of ILC3s to readily produce IL-17 and IL-22 upon stimulation suggests they are integral in an early IL-17/IL-22 response (44, 50). Additionally, IL-17 evolutionarily predates RAG, the protein needed for adaptive immune responses, as demonstrated by its function in invertebrates (51). This suggests that animals developed IL-17-dependent innate immune responses against bacterial pathogens before the advent of Th17 cells. In one of our previous studies using a murine model of K. pneumoniae infection, we found that IL-17R knockout mice had significantly higher bacterial burdens 24 hours post-infection than their wild-type counterparts (52). A similar study infected IL-17R knockout and wild-type mice with K. pneumoniae intratracheally and found that 100% of the IL-17R knockout mice succumbed to infection within 48 hours. By comparison, only 20% of the wild-type mice succumbed to infection within the same time frame (53). Interestingly, intratracheal administration of recombinant CXCL5 was able to decrease bacterial burdens in IL-17R knockout mice within 2 hours of treatment (52). Though CXCL5 is predominantly expressed in epithelial cells, ILC3s have been shown to secrete CXCL5 upon stimulation, further implicating them in bacterial immunity. It has also been demonstrated that IL-23-dependent IL-17 production was the most important for survival against K. pneumoniae challenge in adult mice (54). This is noteworthy as IL-23 is a potent activator of ILC3s (55). Highlighting the importance of IL-17 and IL-22 in response to K. pneumoniae challenge, we demonstrated that bacterial burdens in the lungs dramatically increase upon depletion of both IL-17 and IL-22 (30).

IL-17 has also been demonstrated to play a key role in immunity to S. pneumoniae. In a murine model it was demonstrated that systemic depletion of IL-17 at the time of infection resulted in persistent bacterial burdens in the nasopharynx detectable at day 21 post infection (56), suggesting that IL-17 expression at the time of infection may prevent pneumococcal colonization. Another study found that following pneumococcal vaccination, 95% of mice that produced > 0.3 ng/mL IL-17A upon antigen stimulation were protected from bacterial colonization (57). A murine intranasal vaccination study further illustrates the importance of IL-17A in pneumococcal immunity, as IL-17A neutralization abolished all vaccination protection while IFNγ neutralization had no impact on vaccine efficacy (58). Though this is likely indicative of a Th17 response, ILC3s do not produce IFNγ suggesting they are playing a role in the IL-17 dependent protection (12).

Both IL-17 and IL-22 have proven critical in clearing P. aeruginosa lung infections. A recent study using human sputum samples found that patients with the highest levels of IL-17 prior to being placed on a mechanical ventilator did not get ventilator-associated pneumonia (59). The importance of IL-17 was supported in a murine lung infection model using P. aeruginosa-infused agar beads. In this study, IL-17R knockout mice had inhibited clearance of P. aeruginosa infections. Of note, the authors used a clinical isolate from a cystic fibrosis patient and found that IL-17R knockout mice had exacerbated bacterial burdens and increased weight loss 14 days post-infection. Further, in innate immune cells, IL-17 production appeared to be dependent on ILC3s as 90% of the IL-17-producing CD3+ cells in the lung carried the phenotypic markers for ILC3s (60). Regarding IL-22, it was demonstrated in mice that absence of IL-22 in P. aeruginosa pneumonia enhanced neutrophil recruitment thus exacerbating lung pathology (61). Supporting this, a recent study found that IL-22 upregulated IFNα expression in a murine P. aeruginosa pneumonia model. Increased IFNα correlated with decreased neutrophil
ILC3s in Pulmonary Infections

Studies investigating ILC3s in viral lung infections are very limited, with much of the focus centered on ILC2s (63). However, there have been numerous studies on the effects of IL-22, a key cytokine of ILC3s, in influenza infections. Though IL-22 does not appear to reduce viral titers, it has been demonstrated to reduce disease severity though its functions in tissue repair and regeneration (64, 65). A recent study by Hebert et al. found that inflammation from influenza infection could be significantly reduced by knocking out IL-22 binding protein (IL-22BP, Il22ra2), a soluble inhibitor to IL-22 (66). Additionally, this group showed that Il22ra2-/- knockout mice had enhanced tight junctions during influenza infection promoting tissue integrity (67). Supporting this was the finding that addition of exogenous IL-22 in a murine model of influenza infection limited tissue damage (68).

Expression of IL-22 and IL-17 during viral lung infections also promotes prevention of secondary bacterial infections. Secondary bacterial infections commonly occur after moderate to severe respiratory viral infections and are a significant contributor to morbidity and mortality (69). During the 2009 H1N1 influenza pandemic, up to 26% of case-patients had a bacterial co-infection, which was associated with longer stays in the ICU and a need for mechanical ventilation (70, 71). Currently it is believed that primary infection with a virus impairs the function of mucus and cilia in clearing otherwise normally nonpathogenic bacteria resulting in opportunistic infection (69). As such, it stands to reason that the regenerative properties of IL-22 secreted by ILC3s may function in prevention of secondary bacterial infections. This was recently demonstrated using a murine model of influenza A (IAV) viral infection followed by a secondary S. pneumoniae bacterial infection. The group found that within 2 days of IAV infection there was upregulation of IL-1ß, IL-23, and most importantly IL-22. Further, the group found an increase of RORγt cells and IL-22+ ILC3s in the lung. While IL-22-deficient mice had no change in viral clearance, these same mice had dramatically impaired survival after S. pneumoniae secondary infection (68). A similar study used transgenic IL-22BP knockout mice infected with influenza followed by Staphylococcus aureus or S. pneumoniae challenge. The study found that IL-22BP knockout mice had increased bacterial clearance and decreased mortality from secondary bacterial infection, and improved airway epithelial integrity (72).

IL-17 production during influenza infections was also demonstrated to promote the clearance of secondary bacterial infections. One study using a murine model of IAV infection followed by S. aureus challenge found that overexpression of IL-23 during infection resulted in enhanced production of IL-17 and IL-22 and promoted bacterial clearance (73). It was subsequently demonstrated that IAV infection prior to secondary S. aureus pneumonia inhibited IL-1ß production, decreasing IL-22 and IL-17 expression and worsening the S. aureus infection. Overexpression of IL-1ß during IAV infection rescued the generation of IL-17 and IL-22 and promoted bacterial clearance (74).

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes the acute respiratory disease COVID-19, has been one of the most severe pandemics and public health crises of the last century. As a newly emerged virus, much remains to be elucidated on effective immune responses distinguishing severe and mild disease. As COVID-19 is a respiratory disease that shares some symptoms with influenza, it is possible that ILC3 production of IL-17 and IL-22 also may serve to limit disease severity. In addition to benefits in influenza infection (65, 72), it was recently demonstrated that IL-22 promotes immunity against respiratory syncytial virus; these benefits of IL-22 may also extend to SARS-CoV-2 infection (75). Similar to influenza, it has also been demonstrated that secondary bacterial infections are common in COVID-19 patients. One study found that of 3,338 total COVID-19 patients, 14.3% developed a secondary bacterial infection (76). It is likely IL-17 may also play a role in preventing secondary bacterial infections in COVID-19 patients, though its role has yet to be demonstrated.

Recently, a function for ILCs has been demonstrated in COVID-19. Evaluation of the blood from COVID-19 patients found that severely infected individuals had fewer ILC1, ILC2, and ILC precursor cells than those with mild disease. Additionally, ILCs in severely infected individuals had higher expression of CD69, a marker for activation and tissue homing. The decrease in blood ILCs coupled with the increase in CD69+ ILCs in severely infected individuals suggests that there is more tissue homing to the lungs in severe infections (77). Silverstein et al. corroborate these findings by establishing that a higher ILC abundance in the blood was associated with less time spent in the hospital. Further, hospitalized individuals with COVID-19 had 1.78-fold fewer ILCs in the blood (78). Taken together, these studies illustrate a correlation between decreased ILCs in the blood periphery and severe SARS-CoV-2 infection. As current data regarding ILCs in COVID-19 infections are obtained though analysis of blood, further studies are required to elucidate their exact role in COVID-19 infection since ILCs are predominantly tissue resident.

DISCUSSION

Overall, regulation of ILC3s in both normal and disease states remains an understudied area of research. It is clear these cells contribute significantly to mediating disease as an imbalance of ILC3 has been linked to both COPD and asthma (20, 25). Given their role in barrier protection from invading pathogens, ILC3s or their cytokines could be an ideal target for development of immunotherapies. For example, several groups have FDA approval to study IL-22 in COVID-19 (79, 80) (completed, findings pending). Therefore, it is imperative to develop a complete understanding of how these cells are regulated within
the microenvironment of the lungs, which should enable discovery of novel targets for immunotherapeutic development.

AUTHOR CONTRIBUTIONS

JH, JK, and JM all contributed to writing and editing of the manuscript. All authors contributed to the article and approved the submitted version.

REFERENCES

1. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two Types of Murine Helper T Cell Clone. I. Definition According to Profiles of Lymphokine Activities and Secreted Proteins. *J Immunol* (1986) 136:2348–57.

2. Mosmann TR, Coffman RL. TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties. *Annu Rev Immunol* (1989) 7:145–7. doi: 10.1146/annurev.iy.07.040189.001045

3. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: An Effector CD4 T Cell Lineage With Regulatory T Cell Ties. *Immunity* (2006) 24:677–88. doi: 10.1016/j.immuni.2006.06.002

4. Bettelli E, Korn T, Kuchroo VK. Th17: The Third Member of the Effector T Cell Trilogy. *Curr Opin Immunol* (2007) 19:652–7. doi: 10.1016/j.coi.2007.07.020

5. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors Rorγt and Rorγ. *Immunity* (2008) 28:29–39. doi: 10.1016/j.immuni.2007.11.016

6. Moro K, Yamada T, Tanabe M, Takeuchi T, Ikawa T, Kawamoto H, et al. Innate Production of TH2 Cytokines by Adipose Tissue-Associated C-Kit + Sca-1+ Lymphoid Cells. *Nature* (2010) 463:540–4. doi: 10.1038/ nature08636

7. Fallon PG, Ballantyne SJ, Mangan NE, Barlow JL, Dasvarma A, Hewett DR, et al. Identification of an Interleukin (IL)-25-dependent Cell Population That Provides IL-4, IL-5, and IL-13 At the Onset of Helminth Expulsion. *Nat Med* (2006) 203:1105. doi: 10.1038/nature08949

8. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JKM, et al. A Major Role for IL-17 and Lung Host Defense Against Klebsiella Pneumoniae Infection. *J Exp Med* (2007) 201:117. doi: 10.1084/jem.20061308

9. Kim HY, Lee HJ, Chang Y, Pichavant M, Shore SA, Fitzgerald KA, et al. Interleukin-17+ Innate Lymphoid Cells Regulate Intestinal Homeostasis by Cooperatively Enhance Expression of Antimicrobial Peptides. *J Immunol* (2011) 187:5913–22. doi: 10.4049/jimmunol.1100060

10. Hashimoto-Hill S, Kim M. Migration and Tissue Tropism of Innate Lymphoid Cells in Lymphoid and Nonlymphoid Organs. *J Exp Med* (2015) 212:2117–21. doi: 10.1084/jem.20141172

11. Dutton EE, Camelo A, Sleeman M, Herbst R, Carlesso G, Belz GT, et al. Characterisation of Innate Lymphoid Cell Populations at Different Sites in Mice With Defective T Cell Function. *Welcome Open Res* (2017) 2:117. doi: 10.12688/wellcomeopenres.13199.1

12. De Grove KC, Provoost S, Verhamme FM, Bracke KR, Joos GF, Maes T, et al. Characterization and Quantification of Innate Lymphoid Cell Subsets in Human Lung. *Plos One* (2016) 11:e0145961. doi: 10.1371/journal.pone.0145961

13. Gasteiger G, Fan X, Diky S, Lee SY, Rudensky AJ. Tissue Residency of Innate Lymphoid Cells in Lymphoid and Nonlymphoid Organs. *Sci Adv* (2019) 5:130981–5. doi: 10.1126/sciadv.aax9593

14. Huang Y, Mao K, Chen X, Sun M, Kawai T, Li W, et al. S-Dependent Interorgan Trafficking of Group 2 Innate Lymphoid Cells Supports Host Defense. *Sci Adv* (2018) 359:114–9. doi: 10.1126/science.aam5809

15. Ricardo-Gonzalez RR, Schneider C, Liao C, Lee J, Liang HE, Locksley RM. Tissue-Specific Pathways Extrude Activated ILC2s to Disseminate Type 2 Immunity. *J Exp Med* (2020) 217:e20191172. doi: 10.1084/jem.20191172

16. Forkel M, VanTol S, Hooq C, Michaelsson J, Almer S, Mjoedberg J. Distinct Alterations in the Composition of Mucosal Innate Lymphoid Cells in Newly Diagnosed and Established Crohn’s Disease and Ulcerative Colitis. *J Crohns Colitis* (2013) 7:136–79. doi: 10.1093/ecco-jcc/jjt011

17. Kim HY, Lee HJ, Chang Y, Pichavant M, Shore SA, Fitzgerald KA, et al. Interleukin-17+–producing Innate Lymphoid Cells and the NLRP3 Inflammasome Facilitate Obesity-Associated Airway Hyperreactivity. *Nat Med* (2014) 20:54–61. doi: 10.1038/nm.3423

18. Sawa S, Cherrier M, Lochner M, Sato-Takahayama N, Fehling HJ, Langa F, et al. Lineage Relationship Analysis of Rorγt+ Innate Lymphoid Cells. *Sci Adv* (2020) 330:665–9. doi: 10.1126/sciadv.a1149597

19. Sawa S, Lochner M, Sato-Takahayama N, Dulauroy M, Berard M, Kleinschek M, et al. Rorγt+ Innate Lymphoid Cells Regulate Intestinal Homeostasis by Integrating Negative Signals From the Symbiotic Microbiota. *Nat Immunol* (2011) 12:320–8. doi: 10.1038/ni.2002

20. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. Interleukin (IL)-22 and IL-17 are Coexpressed by Th17 Cells and Cooperatively Enhance Expression of Antimicrobial Peptides. *J Exp Med* (2006) 203:2271–9. doi: 10.1084/jem.20061308

21. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, et al. Interleukin-17 and Lung Host Defense Against Klebsiella Pneumoniae Infection. *Am J Respir Cell Mol Biol* (2001) 25:335–40. doi: 10.1165/rccmb.2001-1202

22. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 Mediates Mucosal Host Defense Against Gram-negative Bacterial Pneumonia. *Nat Med* (2008) 14:275–80. doi: 10.1038/nm1710

23. Golebiowski K, Ros RK, Nagasawa M, van Tol S, Heesters BA, Agmous H, et al. IL-17, IL-23, and TGF-β Drive Plasticity of Human ILC2s Towards IL-17-producing ILCs in Nasal Inflammation. *Nat Commun* (2019) 10:2162. doi: 10.1038/s41467-019-09883-7

FUNDING

JM is supported in part by U54 GM104940 from the National Institute of General Medical Sciences of the National Institutes of Health, which funds the Louisiana Clinical and Translational Science Center, and R01 AI149119. JK and JM are supported by R35HL139930 and R01 AI149119 from the National Institute of Heart, Lung, and Blood, Diseases and the National Institute of Allergy and Infectious Diseases.
32. Bernink JH, Ohme Y, Teunissen MM, Wang J, Wu J, Krabbendam L, et al. C-Kit-Positive ILC2s Exhibit an ILC3-like Signature That may Contribute to IL-17-mediated Pathologies. Nat Immunol (2020) 20:992–1003. doi: 10.1038/s41590-019-0423-0

33. Iwanaga N, Sandquist I, Wanek A, McCombs J, Song K, Kolls JK. Host Immunology and Rational Immunotherapy for Carbapenem-resistant Klebsiella Pneumoniae Infection. JCI Insight (2020) 5:e135591. doi: 10.1172/JCI.insight.135591

34. Simoni Y, Fehlings M, Klaeverpris HN, McGovern N, Koo SL, Loh CY, et al. Human Innate Lymphoid Cell Subsets Possess Tissue-type Based Heterogeneity in Phenotype and Frequency. Immunity (2017) 46:148–61. doi: 10.1016/j.immuni.2016.11.005

35. Maaiz H, Patel N, Sankaranarayanan I, Suzuki Y, Rigas D, Soroosh P, et al. Icosl/icos-ligand Interaction is Required for Type 2 Innate Lymphoid Cell Function, Homeostasis, and Induction of Airway Hyperreactivity. Immunity (2015) 42:538–51. doi: 10.1016/j.immuni.2015.02.007

36. Molofsky AB, Van Goel F, Liang H-E, Van Dyken SJ, Nussbaum JC, Lee J, et al. Interleukin-33 and Interferon-y Counter-regulate Group 2 Innate Lymphoid Cell Activation During Immune Perturbation. Immunity (2015) 43:161–74. doi: 10.1016/j.immuni.2015.05.019

37. Schiering C, Vincent E, Metidji A, Iseppon A, Li Y, Potocnik AJ, et al. Feedback Control of AHR Signalling Regulates Intestinal Immunity. Nature (2017) 542:242–5. doi: 10.1038/nature21080

38. de Araujo EF, Preite NW, Veldhoen M, Loures FV, Calich VLG. Pulmonary Paracoccidioidomycosis in AbF Deficient Hosts is Severe and Associated With Defective Treg and Th22 Responses. Sci Rep (2020) 10:11312. doi: 10.1038/s41598-020-68322-6

39. Michaudel C, Bâille E, Maillot I, Fausconnier L, Colas C, Sokol H, et al. Ozone-Induced Aryl Hydrocarbon Receptor Activation Controls Lung Inflammation Via Interleukin-22 Modulation. Front Immunol (2020) 11:144. doi: 10.3389/fimmu.2020.00144

40. Troeger C, Isles AF, Grimwood K. Necrotizing Pneumonia: An Emerging Problem in Children? Pneumonia (2017) 9:1–19. doi: 10.1186/s11479-007-0035-0

41. Patradora-Ho P, Fitzgerald DA. Lung Abscess in Children. Paediatr Respir Rev (2007) 8:77–84. doi: 10.1016/j.prrv.2006.10.002

42. Gurczynski SJ, Moore BB. IL-17 in the Lung: The Good, the Bad, and the Ugly. Am J Physiol - Lung Cell Mol Physiol (2018) 314:L6–L16. doi: 10.1152/ajplung.00344.2017

43. Van Maele L, Carnoy C, Cayet D, Ivanov S, Porte R, Deruy E, et al. Activation of Type 3 Innate Lymphoid Cells and Interleukin-22 Secretion in the Lungs During Streptococcus Pneumoniae Infection. J Infect Dis (2014) 210:493–503. doi: 10.1093/infdis/jiu016

44. Xiong H, Keith JW, Samilo DW, Carter RA, Leiner IM, Pager E. Innate Lymphocyte/Ly6c Hi Monocyte Crosstalk Promotes Klebsiella Pneumoniae Clearance. Cell (2016) 165:679–89. doi: 10.1016/j.cell.2016.03.017

45. Kinnebrew MA, Buffe CG, Gretchel DE, Zenewicz LA, Hafler JA, et al. Toll-like Receptor 5 Activation. JCI Insight (2017) 3:267–86. doi: 10.1172/JCI.insight.101111

46. Xiong H, Keith JW, Carter RA, Leiner IM, Pager E. Innate Lymphocyte/Ly6c Hi Monocyte Crosstalk Promotes Klebsiella Pneumoniae Clearance. Cell (2016) 165:679–89. doi: 10.1016/j.cell.2016.03.017

47. Hansen M, Jouan Y, Crousat F, Soulard D, Boiseau C, Gonzalez L, et al. Interleukin-17 Protects Against Bacterial Respiratory Infection by Promoting IL-17A-producing Innate T-cell Response. Mucosal Immunol (2020) 13:128–39. doi: 10.1038/s41385-019-0212-y

48. Cao Y, Yang S, Feng C, Zhan W, Zheng Z, Wang Q, et al. Evolution and Function Analysis of interleukin-17 Gene From Pinctada Fucata Martensi. Fish Shellfish Immunol (2019) 88:102–10. doi: 10.1016/j.fsi.2019.02.044

49. Chen K, Edsens T, Trefoce-Nunez G, Way EE, Elsegeiny W, Ricks DM, et al. IL-17 Receptor Signaling in the Lung Epithelium Is Required for Mucosal Chemokine Gradients and Pulmonary Host Defense Against K. Pneumoniae. Cell Host Microbe (2016) 20:596–605. doi: 10.1016/j.chom.2016.10.003

50. Ardain A, Portefield IJZ, Klaeverpris HN, Leslie A. Type 3 ILCs in Lung Disease. Front Immunol (2019) 10:92. doi: 10.3389/fimmu.2019.00092
Infection and Protects Against Secondary Bacterial Infection. *J Virol* (2013) 87:6911–24. doi: 10.1128/jvi.02943-12

69. Prasso JE, Ms JCD. Postviral Complications Bacterial Pneumonia Influenza Respiratory Viruses Bacterial Pneumonia Innate Immunity Interferons. *Clin Chest Med* (2018) 38:127–38. doi: 10.1016/j.ccm.2016.11.006

70. Shieh W-J, Blau DM, Denison AM, DeLeon-Carnes M, Adem P, Bhatnagar J, et al. 2009 Pandemic Influenza A (H1n1). *Am J Pathol* (2010) 177:166–75. doi: 10.2353/ajpath.2010.100115

71. Martin-Loeches I, Sanchez-Corral A, Diaz E, Granada RM, Zaragoza R, Villavicencio C, et al. Community-Acquired Respiratory Coinfection in Critically Ill Patients With Pandemic 2009 Influenza A(H1N1) Virus. *Chest* (2011) 139:555–62. doi: 10.1378/chest.10-1396

72. Aboud RN, McHugh KJ, Rich HE, Ortiz MA, Tobin JM, Ramanan K, et al. IL-22-binding Protein Exacerbates Influenza, Bacterial Super-Infection. *Mucosal Immunol* (2019) 12:1231–43. doi: 10.1038/s41385-019-0188-7

73. Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slichter SR, et al. Influenza A Inhibits Th17-Mediated Host Defense Against Bacterial Pneumonia in Mice. *J Immunol* (2011) 186:1666–74. doi: 10.4049/jimmunol.1002194

74. Robinson KM, Choi SM, McHugh KJ, Mandalapu S, Enelow RI, Kolls JK, et al. Influenza A Exacerbates Staphylococcus Aureus Pneumonia by Attenuating IL-1β Production in Mice. *J Immunol* (2013) 191:5153–9. doi: 10.4049/jimmunol.1301237

75. Das S, St. Croix C, Good M, Chen J, Zhao J, Hu S, et al. Interleukin-22 Inhibits Respiratory Syncytial Virus Production by Blocking Virus-Mediated Subversion of Cellular Autophagy. *iScience* (2020) 23:101256. doi: 10.1016/j.isci.2020.101256

76. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial Co-Infection and Secondary Infection in Patients With COVID-19: A Living Rapid Review and Meta-Analysis. *Clin Microbiol Infect* (2020) 26:1622–9. doi: 10.1016/j.cmi.2020.07.016

77. Garcia M, Kokkinoou E, Carrasco Garcia A, Parrot T, Palma Medina LM, Maleki KT, et al. Innate Lymphoid Cell Composition Associates With COVID-19 Disease Severity. *Clin Transl Immunol* (2020) 9:e1224. doi: 10.1002/cti2.1224

78. Silverstein NJ, Wang Y, Manickas-Hill Z, Carbone CC, Dauphin A, Li JZ, et al. Innate Lymphoid Cells and Disease Tolerance in SARS-CoV-2 Infection. *medRxiv Prepr Serv Heal Sci* (2021) Preprint. doi: 10.1101/2020.11.14.21249839

79. ClinicalTrials.gov. Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19 (2020). https://clinicaltrials.gov/ct2/show/NCT04498377 [Accessed April 19, 2021].

80. ClinicalTrials.gov. A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia (COVASTIL) (2020). https://clinicaltrials.gov/ct2/show/NCT04386616 [Accessed April 19, 2021].

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Hoffmann, Kolls and McCombs. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.